John Brognard

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas”.

The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas

Journal of Biological Chemistry(2024)10.1016/j.jbc.2024.107615

N/A

0.377DataRank · unranked

8 citations

Sabrina Hanson, Ben King, Katherine M. Nyswaner, Kelcie Foss, Noelle Tesi +8 more

TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin

Cancer Discovery(2021)10.1158/2159-8290.cd-20-0797

N/A

0DataRank · unranked

57 citations

Elvira An, Katherine M. Nyswaner, Ryan C. Bensen, Daniel A. Ritt, Suzanne I. Specht +15 more

Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer

Molecular Pharmacology(2022)10.1124/molpharm.121.000306

N/A

0DataRank · unranked

13 citations

John Brognard, Pedro Torres‐Ayuso

PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer

Cell chemical biology(2023)10.1016/j.chembiol.2023.10.023

N/A

0DataRank · unranked

15 citations

Meghri Katerji, Dawid Mehlich, Sophia A. Lookingbill, Venkata R. Sabbasani, Hope Liou +9 more

TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0412

N/A

0DataRank · unranked

8 citations

Francesca A. Carrieri, Nick Connis, Audrey Lafargue, Jinhee Chang, Aaron Chan +13 more

Selective Degradation of MLK3 by a Novel CEP1347-VHL-02 PROTAC Compound Limits the Oncogenic Potential of TNBC

Journal of Medicinal Chemistry(2024)10.1021/acs.jmedchem.4c00577

N/A

0DataRank · unranked

8 citations

Dawid Mehlich, Venkata R. Sabbasani, Michał Łomiak, Pedro Torres‐Ayuso, Katarzyna Wróbel +6 more

Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors

Science Signaling(2025)10.1126/scisignal.ado2857

N/A

0DataRank · unranked

9 citations

Meghri Katerji, Marwa M. Afifi, Katherine M. Nyswaner, Carolyn C. Woodroofe, Zoe C. Edwards +22 more

CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor–driven proteome through PARP7 activity

Proceedings of the National Academy of Sciences(2025)10.1073/pnas.2424985122

N/A

0DataRank · unranked

8 citations

Joao A. Paulo, Christina B. Schroeter, Melanie Lad, Abigail Shurr, Chara Mastrokalou +9 more

Discovery of potent and selective PROTACs for the protein kinase LZK for the treatment of head and neck cancer

Journal of Biological Chemistry(2025)10.1016/j.jbc.2025.108452

N/A

0DataRank · unranked

2 citations

K. Bergman, Eric Lindberg, Maxine R. Rubin, Marwa Afifi, Amy L. Funk +9 more

The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells

Journal of Biological Chemistry(2020)10.1074/jbc.ra119.012365

N/A

0DataRank · unranked

30 citations

Katherine M. Nyswaner, Pedro Torres‐Ayuso, John Brognard, Van T. Hoang

Defeating kinases that promote tumorigenesis through non-catalytic functions with PROTACs - PIM kinase as an example

Expert Opinion on Therapeutic Targets(2025)10.1080/14728222.2025.2500418

N/A

0DataRank · unranked

0 citations

John Brognard, Pedro Torres‐Ayuso